EOM Pharmaceuticals Holdings, Inc. (IMUC)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 10:20AM EDT
| Previous close | 0.1990 |
| Open | 0.1255 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.1255 - 0.1990 |
| 52-week range | 0.1000 - 0.4000 |
| Volume | |
| Avg. volume | 3,250 |
| Market cap | 22.541M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 0.02 |
| EPS (TTM) | 11.0600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key pro-inflammatory and anti-inflammatory cytokines with potential therapeutic utility in treating a variety of acute and chronic inflammatory conditions.
- PR Newswire
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil.
© 2024 Yahoo. All rights reserved.